Last reviewed · How we verify
NCT07207824: HERO
DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC
Phase 3 trial testing Active Comparator: BCG induction and maintenance in Bladder (Urothelial, Transitional Cell) Cancer in 182 participants. Not yet recruiting.
1 June 2030
Quick facts
| Lead sponsor | Fudan University |
|---|---|
| Phase | Phase 3 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 182 |
| Start date | 1 December 2025 |
| Primary completion | 1 June 2030 |
| Estimated completion | 1 December 2030 |
| Sites | 1 location across China |
Drugs / interventions tested
- Active Comparator: BCG induction and maintenance — full drug profile →
- DV + BCG induction and maintenance — full drug profile →
Conditions studied
- Bladder (Urothelial, Transitional Cell) Cancer — all drugs for Bladder (Urothelial, Transitional Cell) Cancer →
- NMIBC — all drugs for NMIBC →
Sponsor
Fudan University
Who can join
18 and older, any sex, with Bladder (Urothelial, Transitional Cell) Cancer or NMIBC. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to learn about the safety and effects of the study medicine (Disitamab Vedotin) in people with non-muscle invasive bladder cancer. This study is seeking participants whose bladder cancer is still in early stages, has not spread outside of the bladder, has been removed with surgery, and is high risk. Each participant was assigned to one of two study treatment groups: One group is given Disitamab Vedotin and BCG.The second group is given BCG only and will not receive Disitamab Vedotin.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07207824
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Bladder (Urothelial, Transitional Cell) Cancer
Currently open trials in the same condition.
- NCT07589413 — Association Between Irrigation Fluid Absorption and Perioperative cfDNA Dynamics After TURBT · recruiting
- NCT07067749 — Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer · Phase 3 · recruiting
- NCT06787053 — Selecting Hypoxic Tumours for Treatment Modification · recruiting
- NCT06696742 — PD1 Inhibitors Combined With Clostridium Butyricum for Urothelial Carcinoma · Phase 2 · recruiting
Other Fudan University trials
Trials by the same sponsor.
- NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
- NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
- NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
- NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
- NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07207824 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fudan University
- Last refreshed: 6 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07207824.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing